- Home
- HIX vs CATX Comparison
HIX vs CATX Comparison
Compare HIX & CATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HIX | CATX |
|---|---|---|
| Founded | 1998 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 354.9M | 341.0M |
| IPO Year | 1998 | 2018 |
Fundamental Metrics
Financial Performance| Metric | HIX | CATX |
|---|---|---|
| Price | $3.94 | $3.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $12.11 |
| AVG Volume (30 Days) | 327.9K | ★ 1.1M |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | ★ 13.14% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.75 | $1.96 |
| 52 Week High | $4.39 | $6.16 |
Technical Indicators
Market Signals| Indicator | HIX | CATX |
|---|---|---|
| Relative Strength Index (RSI) | 49.76 | 57.25 |
| Support Level | $3.89 | $2.82 |
| Resistance Level | $4.04 | $3.78 |
| Average True Range (ATR) | 0.04 | 0.18 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 54.55 | 65.62 |
Price Performance
Historical ComparisonAbout HIX Western Asset High Income Fund II Inc.
Western Asset High Income Fund II Inc is a diversified closed-end management investment company. Its primary investment objective is to maximize current income by investing at least 80% of its net assets, plus any borrowings for investment purposes, in high-yield debt securities. As a secondary objective, the Fund seeks capital appreciation to the extent consistent with its objective of seeking to maximize current income.
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.